

# Bebtelovimab

## COVID positive with

- High Risk medical condition
- < 7 days of symptoms

No

Routine care

Yes

## TIER 1

- 1) Significant immunosuppression- B cell depleting therapy/Transplantation/Primary Immunodeficiency
- 2) Pregnancy- unvaccinated and moderate symptoms
- 3) Immunosuppression - > 20 mg prednisone/daily or other immunosuppressive agents

Yes

## Active Treatment

### Preferred Therapy:

- Bebtelovimab preferred (< 7 d of sx )

### Alternative Therapy:

- Paxlovid (< 5 d of sx)
  - No data in pregnancy

No

# Bebtelovimab

## COVID positive with

- High Risk medical condition
- < 7 days of symptoms

Does Not Qualify by Tier 1

## TIER 2

Tier 2a : Immunosuppression - other immunosuppressive agents

Tier 2b : Unvaccinated with 1 of the following

- 1) Age > 65
- 2) BMI > 35
- 3) Chronic Lung Disease
- 4) Sickle Cell Disease with history of Sickle Chest
- 5) Untreated HIV or Advanced disease

Yes

No

## Active Treatment

### Preferred Therapy:

- Paxlovid (< 5 d of sx)
  - No data in pregnancy

### If Paxlovid is contraindicated -

- Bebtelovimab preferred (< 7 d of sx )
- Molnupiravir (<5 days of sx)

# Bebtelovimab

## COVID positive with

- High Risk medical condition
- < 7 days of symptoms

Does Not Qualify by Tier 1 or 2

## TIER 3

### Unvaccinated with at least 1 of the following

- Obesity (Body Mass Index [BMI] >30 kg/cm<sup>2</sup>)
- Chronic kidney disease
- Type I or II diabetes mellitus
- Cardiovascular disease or hypertension
- Sickle cell disease
- Neurodevelopmental disorders or other conditions that confer medical complexity (e.g., cerebral palsy, genetic or metabolic syndromes)
- Medical technological dependence (e.g., tracheostomy, gastrostomy, etc.)

### Vaccinated with at least 1 of the following

- Age ≥65 years
- Morbid obesity (Body Mass Index [BMI] >35 kg/cm<sup>2</sup>)
- Pregnancy
- Chronic lung disease (COPD, moderate-severe asthma, interstitial lung disease, obstructive sleep apnea, cystic fibrosis or pulmonary hypertension)

Yes

## Active Treatment

### Preferred Therapy:

- Paxlovid (< 5 d of sx)
  - No data in pregnancy

### If Paxlovid is contraindicated -

- Bebtelovimab preferred (< 7 d of sx )
- Molnupiravir (<5 days of sx)

# Bebtelovimab

## COVID positive with

- High Risk medical condition
- < 7 days of symptoms

Does Not Qualify by Tier 1, 2, or 3

## TIER 4

Any of the following conditions as outlined in the Bebtelivumab EUA (regardless of vaccine status), i.e. comprehensive list of we have an unlimited supply available.

- Older age  $\geq 65$  years
- Obesity or being Overweight (Body Mass Index [BMI]  $>25$  kg/cm<sup>2</sup>)
- Pregnancy
- Chronic kidney disease
- Type I or II diabetes mellitus
- Immunosuppression (from a condition or medication); see list below
- Cardiovascular disease or hypertension
- Chronic lung disease (COPD, moderate-severe asthma, interstitial lung disease, obstructive sleep apnea, cystic fibrosis or pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders or other conditions that confer medical complexity (e.g., cerebral palsy, genetic or metabolic syndromes)
- Medical technological dependence (e.g., tracheostomy, gastrostomy, etc.)

Yes

## Active Treatment

### Preferred Therapy:

- Paxlovid (< 5 d of sx)
  - No data in pregnancy

### If Paxlovid is contraindicated -

- Bebtelovimab preferred (< 7 d of sx )
- Molnupiravir (<5 days of sx)

# Bebtelovimab

## Indication

- Treatment of mild to moderate Covid infection not requiring hospital admission
- Adults >18yo and pediatric patients  $\geq$ 12yo and weighing >40kg

## Dosing

- 175mg/2mL for all patients
- 1 dose = 1 vial = 2mL

## Storage

- Stored in GED Omnicell refrigerator A (small fridge)

## Administration

- IV over 30 seconds
- Allow vial to come to room temperature prior to administration

## Monitoring

- Monitor patient for 1 hour post-administration
- Caution: hypersensitivity and infusion site reactions